Skip to main content
SpringerLink
Log in
Book cover

The Treatment of Medical Problems in the Elderly pp 215–258Cite as

Management of Parkinson’s disease in the elderly

  • Chapter

Part of the book series: Current Status of Modern Therapy ((TCSMT,volume 3))

Abstract

Parkinson’s disease is one of the commonest neurological conditions in Great Britain and in America but its incidence and prevalence have been little studied. Incidence rates, which measure the number of new cases per unit population per year, are useful for acute onset conditions, but misleading for diseases of insidious onset as many early cases can be missed. Prevalence rates, which measure the number of cases per unit population on a given date, are more useful for more chronic conditions such as Parkinson’s disease. In 1952 Garland1 found a prevalence rate of 59 cases per 100 000 of the general population in the Leeds area, a rate which he regarded as approximate and minimal. Brewis et al. in 19662 reported an overall prevalence rate of 112·5 per 100 000 in the Carlisle population of 1961, and showed the rates for different age groups. They believed that Parkinsonism was underdiagnosed and therefore that their figure was an underestimate. An American study by Kurland in 1958 in Rochester3 showed a greater prevalence than that at Carlisle for each age group, and the overall prevalence rate was 187 per 100 000. They believed that their survey, using the facilities of the Mayo clinic, was far more complete than previous ones.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Garland, H. G. (1952). Parkinsonism. Br. Med. J, 1, 153

    PubMed  CAS  Google Scholar 

  2. Brewis, M., Poskanzer, D. C., Rolland, C. and Miller, H. (1962). Neurological disease in an English city. Acta Neurol. Scand, 24 (Suppl.) 42, 31

    Google Scholar 

  3. Kurland, L. T. (1958). In: W. S. Fields (ed.). Pathogenesis and Treatment of Parkinsonism, p5. (Springfield, 111.: Charles C. Thomas )

    Google Scholar 

  4. Gudmundsson, K. R. (1967). A clinical survey of Parkinsonism in Iceland. Acta Neurol. Scand, 33 (Suppl), 43,

    Google Scholar 

  5. Parkinson’s Disease (1974). Studies of Current Health Problems No. 51. ( London: Office of Health Economics )

    Google Scholar 

  6. Hoehn, M. M. and Yahr, M. D. (1967). Parkinsonism: onset, progression and mortality. Neurology, 17, 427

    PubMed  CAS  Google Scholar 

  7. Harris, A. I. (1971). Handicapped and Impaired in Great Britain ( London: HMSO )

    Google Scholar 

  8. Sweet, R. D. and McDowell, F. H. (1975). Five years treatment of Parkinson’s disease with levodopa: therapeutic results and survival of 100 patients. Ann. Intern. Med, 83, 456

    PubMed  CAS  Google Scholar 

  9. Rinne, U. K. (1978). Recent advances in research on Parkinsonism. Acta Neurol Scand, 67 (Suppl.) 57, 77

    Google Scholar 

  10. Critchley, M. (1929). Arteriosclerotic Parkinsonism. Brain, 52, 23

    Google Scholar 

  11. Parkes, J. D., Marsden, C. D., Rees, J. E., Curzon, G., Katamaneni, B. D., Knill-Jones, R., Akbar, A., Das, S., and Kataria, M. (1974). Parkinson’s disease, cerebral arteriosclerosis and senile dementia. Q. J. Med, 43, 49

    PubMed  CAS  Google Scholar 

  12. Locket, S. (1957). Clinical Toxicology. ( London: Kimpton )

    Google Scholar 

  13. Smith, J. S., and Brandon, S. (1970). Acute carbon monoxide poisoning - three years’ experience in a defined population. Postgrad. Med. J, 46, 65

    PubMed  CAS  Google Scholar 

  14. Parkinson, J. (1817). An Essay on the Shaking Palsy. (London: Sherwood, Neely and Jones )

    Google Scholar 

  15. Nowack, W. J., Hatelid, J. M. and Sohn, R. S. (1977). Dysphagia in Parkinsonism. Arch. Neurol, 34, 320

    PubMed  CAS  Google Scholar 

  16. Logemann, J. A., Blonsky, E. R. and Boshes, B. (1970). Dysphagia in Parkinsonism. J. Am. Med. Assoc 231, 69

    Google Scholar 

  17. Webster, D. D. (1968). Critical analysis of the disability in Parkinson’s disease. Mod. Treatment, 5, 257

    CAS  Google Scholar 

  18. Mehta, A. D., Wright, W. B. and Kirby, B. J. (1978). Ventilatory function in Parkinson’s Disease. Br. Med. J, 1, 1456

    PubMed  CAS  Google Scholar 

  19. Wartenberg, R. (1952). Head-dropping test. Br. Med. J, 1, 687

    PubMed  CAS  Google Scholar 

  20. Hildick-Smith, M. (1976). Assessing dementia in the older Parkinsonian patient. Mod. Geriatr, 6, 33

    Google Scholar 

  21. Hodkinson, H. M. (1972). Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing, 1, 233

    PubMed  CAS  Google Scholar 

  22. Greenfield, J. G. and Bosanquet, F. D. (1953). The brainstem lesions in Parkinsonism. J. Neurol. Neurosurg. Psychiatry, 16, 213

    PubMed  CAS  Google Scholar 

  23. Pearce, J. M. S. (1978). Aetiology and natural history of Parkinson’s disease. Br. Med. J, 4, 1664

    Google Scholar 

  24. Ehringer, H. and Hornykiewicz, O. (1960). Verteilung von Noradrenalin und Dopamin im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr, 38, 1236

    PubMed  CAS  Google Scholar 

  25. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. and Seiteiberger (1965). Zur Differenzierung des Parkinson - Syndroms. Proceedings of 8th Inter-national Congress of Neurology, p. 145 ( Vienna: Medical Academy )

    Google Scholar 

  26. Birkmayer, W. and Hornykiewicz, O. (1961). Der L-3, 4 dioxyphenylalanin (= DOPA) Effekt bei der Parkinsonakinese. Wien. Klin. Wochenschr, 73, 787

    PubMed  CAS  Google Scholar 

  27. Barbeau, A., Sourkes, T. L. and Murphy, G. F. (1962). Les catecholamines dans la maladie de Parkinsonism. In J. de Ajuriaguerra (ed). Monoamines et Système Nerveux Centrale, p. 247. ( Paris: Masson )

    Google Scholar 

  28. Rinne, U. K., Riekkinen, P., Sonninen, V. and Laaksonen, H. (1973). Brain acetylcholinesterase in Parkinson’s disease. Acta Neurol. Scand, 49, 215

    PubMed  CAS  Google Scholar 

  29. Bowen, D. M. and Davison, A. N. (1978). Biochemical changes in the normal ageing brain. In B. Isaacs (ed). Recent Advances in Geriatric Medicine, p. 54. ( Edinburgh, London and New York: Churchill Livingstone )

    Google Scholar 

  30. Lewis, C., Ballinger, B. R. and Presly, A. S. (1978). Trial of levodopa in senile dementia. Br. Med. J, 1, 550

    PubMed  CAS  Google Scholar 

  31. Birkmayer, W., Ambrozi, L., Neumayer, E. and Riederer, P., (1974). Longevity in Parkinson’s disease treated with L-dopa. Clin. Neurol Neurosurg, 1, 15

    Google Scholar 

  32. Duvoisin, R. C. (1969), In Crane, G. E. and Gardiner, R. Jr. (eds.). Psychotropic Drugs and Dysfunction of Basal Ganglia, p. 134 ( Washington: US Public Health Services )

    Google Scholar 

  33. Hughes, R. C., Polgar, J. G., Weightman, D. and Walton, J. N. (1971), L-dopa in Parkinsonism - the effects of withdrawal of anticholinergic drugs. Br. Med. J, 2, 487

    Google Scholar 

  34. Broe, G. A. and Caird, F. I. (1973). Levodopa for Parkinsonism in elderly and demented patients. Med. J. Aust, 1, 630

    PubMed  CAS  Google Scholar 

  35. Caird, F. I. (1974). Parkinsonism. In Anderson W. F. and Judge T. C. (eds.). Geriatric Medicine, pp. 171–183 ( London and New York: Academic Press )

    Google Scholar 

  36. Caird, F. I. and Williamson J. (1978). Drugs for Parkinson’s disease. Lancet, i, 986

    Google Scholar 

  37. Mindham, R. H., Lamb, P. and Bradley, R. (1977). A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced Parkinsonism. Br. J. Psychiatry 130, 581

    Google Scholar 

  38. Schwab, R. S., England, A. C., Poskanzer, D. C. and Young, R. R. (1969). Amantadine in the treatment of Parkinson’s disease. J. Am. Med. Assoc, 208, 1168

    CAS  Google Scholar 

  39. Cotzias, G. C., van Woert, M. H. and Schiffer, L. M. (1967). Aromatic amino- acids and modification of Parkinsonism. N. Engl. J. Med, 276, 374

    PubMed  CAS  Google Scholar 

  40. Calne, D. B., Spiers, A. S., Stern, G. M., Lawrence, D. R. and Armitage, P. (1969). L-dopa in idiopathic Parkinsonism. Lancet, ii, 973

    Google Scholar 

  41. Godwin-Austen, R. B., Tomlinson, E. B., Frears, C. C. and Kok, H. W. L. (1969). Effects of L-dopa in Parkinson’s disease. Lancet, ii, 165

    Google Scholar 

  42. Yahr, M. D., Duvoisin, R. C., Hoehn, M. M., Schear, M. and Barrett, R. E. (1968). L-dopa, its clinical effects in Parkinsonism. Trans. Am. Neurol. Assoc, 93, 56

    PubMed  CAS  Google Scholar 

  43. Mawdsley, C. (1970). Treatment of Parkinsonism with Laevodopa. Br. Med. J, 1, 331

    PubMed  CAS  Google Scholar 

  44. Jenkins, R. B. and Groh, R. H. (1970). Mental symptoms in Parkinsonian patients treated with L-dopa. Lancet, ii, 177

    Google Scholar 

  45. Godwin-Austen, R. B., Bergmann, S. and Frears, C. C. (1971b). Effect of age and arteriosclerosis on the response of Parkinsonian patients to levodopa. Br. Med. J, 4, 522

    PubMed  CAS  Google Scholar 

  46. God win-Austen, R. B., Frears, C. C. and Bergmann, S. (1971a). Incidence of side-effects from levodopa during the introduction of treatment. Br. Med. J, 1, 267

    PubMed  CAS  Google Scholar 

  47. Peaston, M. J. T. and Bianchine, J. R. (1970). Metabolic studies and clinical observations during L-dopa treatment of Parkinson’s disease. Br. Med. J, 1, 400

    PubMed  CAS  Google Scholar 

  48. Leader (1978). Drugs for Parkinson’s disease. Lancet, i, 754

    Google Scholar 

  49. Sutcliffe, R. L. G. (1973). L-dopa therapy in elderly patients with Parkinsonism. Age Ageing, 2, 34

    Google Scholar 

  50. Vignalou, J. and Beck, H. (1973). La L-dopa chez 122 Parkinsoniens de plus de 70 ans. Gerontol. Clin, 15, 50

    CAS  Google Scholar 

  51. Hildick-Smith, M. (1973). The patient’s view of L-dopa after one year’s therapy. Gerontol. Clin, 15, 74

    CAS  Google Scholar 

  52. Hildick-Smith, M. (1973). Pyridoxine in Parkinsonism. Lancet, ii, 1029

    Google Scholar 

  53. Hunter, K. R., Hollman, A., Laurence, D. R. and Stern, G. M. (1971), Levodopa in Parkinsonian patients with heart disease. Lancet, i, 932

    Google Scholar 

  54. Marsden, C. D., Parkes, J. D. and Rees, J. E. (1973). A year’s comparison of treatment of patients with Parkinson’s disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet, ii, 1459

    Google Scholar 

  55. Cotzias, G. C., Papavasiliou, P. S. and Gellene, R. (1969). Modification of Parkinsonism - chronic treatment with L-dopa. N. Engl. J. Med, 280, 337

    PubMed  CAS  Google Scholar 

  56. Diamond, S. G., Markham, C. H. and Treciokas, L. J. (1978). A double-blind comparison of Levodopa, Madopa and Sinfcmet in Parkinson’s Disease. Ann. Neurol, 3, 267

    PubMed  CAS  Google Scholar 

  57. Korten, J. J., Keyser, A., Joosten, M. G. and Gabreels, F. J. M. (1975). Madopar versus Sinemet. Eur. Neurol, 13, 65

    PubMed  CAS  Google Scholar 

  58. Martin, W. E., Toloso, E. S., Loewenson, R. B., Lee, M. C., Resch, J. A. and Baker, A. B. (1976). Safer drug treatment for patients with Parkinson’s disease. Mod. Geriatr, 6, (no. 2) 11

    Google Scholar 

  59. Marsden, C. D., Barry, P. E., Parkes, J. D. and Zilkha, K. J. (1973). Treatment of Parkinson’s disease with levodopa combined with L-alpha- methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase. J. Neurol. Neurosurg. Psychiatry, 36, 10

    PubMed  CAS  Google Scholar 

  60. Critchley, E. (1975). L-dopa and carbidopa (sinemet) in the management of Parkinsonism. Postgrad. Med. J, 51, 619

    PubMed  CAS  Google Scholar 

  61. Mars, H. and Krall, J. (1971). L-dopa and cardiac arrhythmias. N. Engl J. Med, 285, 1437

    PubMed  CAS  Google Scholar 

  62. Calne, D. B, Petrie, A., Rao, S., Reid, J. L. and Vakil, S. D. (1972). Action of L-alpha-methyldopahydrazine on the blood pressure of patients receiving levodopa. Br. J. Pharmacol, 44, 162

    PubMed  CAS  Google Scholar 

  63. Klawans, H. L., Ringel, S. P. and Shenker, D. M. (1971). Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor. J. Neurol Neurosurg. Psychiatry, 34, 682

    PubMed  CAS  Google Scholar 

  64. Barbeau, A., Mars, H., Botez, M. I. and Joubert, M. (1972). Levodopa combined with peripheral decarboxylase inhibition in Parkinson’s disease. Canad. Med. Assoc. J, 106, 1169

    PubMed  CAS  Google Scholar 

  65. Hildick-Smith, M. (1976). Alternatives to levodopa. Br. Med. J, 1, 1406

    PubMed  CAS  Google Scholar 

  66. Hunter, K. R, Laurence, D. R, Shaw, K. M. and Stern, G. M. (1973). Sustained levodopa therapy in Parkinsonism. Lancet, ii, 929

    Google Scholar 

  67. Barbeau, A. (1976). Six years of high-level levodopa therapy in severely akinetic Parkinsonian patients. Arch. Neurol, 33, 333

    PubMed  CAS  Google Scholar 

  68. Sweet, R. D., and McDowell, F. (1974). The on — off response to chronic L-dopa treatment of Parkinsonism. In McDowell, F. H. and Barbeau, A. (eds.). Advances in Neurology, 5, p. 331. ( New York: Raven Press )

    Google Scholar 

  69. Marsden, C. D. and Parkes, J. D. (1976). On — off effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet, i, 292

    Google Scholar 

  70. Yahr, M. D. (1977). Longterm levodopa in Parkinson’s disease. Lancet, i, 706

    Google Scholar 

  71. Calne, D. B., Teychenne, P. F., Claveria, L. E., Eastmann, R., Greenacre, J. K. and Petrie, A. (1974). Bromocriptine in Parkinsonism. Br. Med. J, 4, 442

    PubMed  CAS  Google Scholar 

  72. Kartzinel, R., Teychenne, P., Gillespie, M. M., Perlow, M., Gielen, A. C., Sadowsky, D. A. and Calne, D. B. (1976). Bromocriptine and levodopa (with or without carbidopa) in Parkinsonism. Lancet, ii, 272

    Google Scholar 

  73. Parkes, J. D., Debono, A. G. and Marsden, C. D. (1976). Bromocriptine in Parkinsonism: longterm treatment, dose response and comparison with levodopa. J. Neurol Neurosurg. Psychiatry, 39, 1101

    PubMed  CAS  Google Scholar 

  74. Marsden, C. D. and Parkes, J. D. (1976). Bromocriptine in Parkinsonism. Lancet, ii, 419

    Google Scholar 

  75. Wass, J. A. H., Thorner, M. O. and Besser, G. M. (1976). Digital vasospasm with bromocriptine. Lancet, i, 1135

    Google Scholar 

  76. Calne, D. B., Plotkin, C., Williams, A. C., Nutt, J. G., Neophytides, A. and Teychenne, P. F. (1978). Longterm treatment of Parkinsonism with bromocriptine. Lancet, i, 735

    Google Scholar 

  77. Bédard, P., Parkes, J. D. and Marsden, C. D. (1978). Effect of new dopamine- blocking agent (oxiperomide) in drug-induced dyskinesias in Parkinson’s disease and spontaneous dyskinesias. Br. Med. J, 1, 954

    PubMed  Google Scholar 

  78. Birkmayer, W. (1976). Medical treatment of Parkinson’s disease: General review, past and present. In Birkmayer, W. and Hornykiewicz, O. (eds). Advances in Parkinsonism, pp. 407–424 ( Basle: Roche )

    Google Scholar 

  79. Quaglieri, C. E. and Celesia, G. G. (1977). Effect of thalamotomy and L-dopa therapy on the speech of Parkinsonian patients. Eur. Neurol, 15, 34

    PubMed  CAS  Google Scholar 

  80. Selby, G. (1976). The influence of previous stereotactic thalamotomy on L-dopa treatment in Parkinson’s disease. Proc. Aust. Assoc. Neurol, 13, 55

    PubMed  CAS  Google Scholar 

  81. Greer, M. (1976). How to achieve maximum benefit for the patient with Parkinson’s disease. Geriatrics, 31, 89

    PubMed  CAS  Google Scholar 

  82. Rampton, D. S. (1977). Hypertensive crisis in a patient given sinemet, metoclo- pramide and amitryptiline. Br. Med. J, 2, 607

    PubMed  CAS  Google Scholar 

  83. Hausner, R. (1976). Drugs that reduce efficacy of levodopa. N. Engl. J. Med, 295, 1538

    PubMed  CAS  Google Scholar 

  84. Ball, B. (1882). De l’insanité dans la paralysie agitante. Encephale, 2, 22

    Google Scholar 

  85. Loranger, A. W, Goodell, H., McDowell, F. H., Lee, J. E., and Sweet, R. D. (1972). Intellectual impairment in Parkinson’s syndrome. Brain, 95, 405

    PubMed  CAS  Google Scholar 

  86. Celesia, G. C. and Wannamaker, W. M. (1972). Psychiatric disturbances in Parkinson’s disease. Dis. Nerv. Syst, 33, 577

    PubMed  CAS  Google Scholar 

  87. Eadie, M. J. and Sutherland, J. M. (1964). Arteriosclerosis in Parkinsonism. J. Neurol. Neurosurg. Psychiatry, 27, 237

    PubMed  CAS  Google Scholar 

  88. Pearce, J. (1974). Mental changes in Parkinsonism. Br. Med. J, 2, 445

    PubMed  CAS  Google Scholar 

  89. Sacks, O. W., Messeloff, C, Schartz, W, Goldfarb, A. and Kohl, M. (1970). Effects of L-dopa in patients with dementia. Lancet, i, 1231

    Google Scholar 

  90. Wolf, S. M. and Davis, R. L. (1973). Permanent dementia in idiopathic Parkinsonism treated with levodopa. Arch. Neurol, 29, 276

    PubMed  CAS  Google Scholar 

  91. Drachman, D. A. and Stahl (1975). Extrapyramidal dementia and levodopa. Lancet, i, 809

    Google Scholar 

  92. Pollock, M. and Hornabrook, R. W. (1966). The prevalence, natural history and dementia of Parkinsonism. Brain, 89, 429

    PubMed  CAS  Google Scholar 

  93. Davis, J. C. (1977). Team management of Parkinson’s disease. Am. J. Occup. Ther, 31, (no. 5)-300

    Google Scholar 

  94. Hurwitz, L. J. (1964). Improving mobility in severely disabled Parkinsonian patients. Lancet, ii, 953

    Google Scholar 

  95. Singer, E. (1973). Social costs of Parkinson’s disease. J. Chron. Dis, 26, 243

    PubMed  CAS  Google Scholar 

  96. God win-Austen, R. B. (1971). Parkinson’s Disease. A booklet for patients and their families, published and distributed by the Parkinson’s Disease Society, 81 Queen’s Road, London

    Google Scholar 

  97. Parkinson’s Disease Day to Day. A further booklet published by the Parkinson’s Disease Society, London

    Google Scholar 

Reviews

  • Jewesbury, E. C. O. (1970). Parkinsonism. Br. J. Hosp. Med, 4, 825

    Google Scholar 

  • Leader (1974). Mental changes in Parkinsonism. Br. Med. J, 2, 1

    Google Scholar 

  • Bianchine, J. R. and Sunyapridakul L. (1974). Individualisation of levodopa therapy. Med. Clin. N. Am, 58, 1071

    PubMed  CAS  Google Scholar 

  • Davison, W. (1974). Management of Parkinsonism. Mod. Geriatr 4, 102

    Google Scholar 

  • Hornekiewicz, O. (1975). Parkinson’s disease and its chemotherapy. Biochem. Pharmacol, 24, 1061

    Google Scholar 

  • Barbeau, A. (1975). Longterm assessment of levodopa therapy in Parkinson’s disease. Canad. Med. Assoc. J, 112, 1379

    PubMed  CAS  Google Scholar 

  • Yahr, M. D. (1975). Levodopa. Ann. Intern. Med, 83, 677

    PubMed  CAS  Google Scholar 

  • Calne, D. B. (1976). Developments in the treatment of Parkinsonism. N. Engl. J. Med, 295, 1433

    PubMed  CAS  Google Scholar 

  • Bianchine. J. (1976). Drug therapy of Parkinsonism. N. Engl. J. Med, 295, 814

    PubMed  CAS  Google Scholar 

  • Leader (1976). Alternatives to levodopa. Br. Med. J, 1, 1169

    Google Scholar 

  • Curzon, G. (1977). The biochemistry of the basal ganglia and Parkinson’s disease. Postgrad. Med. J, 53, 719

    PubMed  CAS  Google Scholar 

  • Godwin-Austen, R. B. (1977). The treatment of Parkinson’s disease. Postgrad. Med. J, 53, 729

    PubMed  CAS  Google Scholar 

  • Marsden, C. D. and Parkes, J. D. (1977). Success and problems of longterm levodopa therapy in Parkinson’s disease. Lancet, i, 345

    Google Scholar 

  • Duvoisin, R. C. (1977). Problems in the treatment of Parkinsonism. In Messiha, F. S. and Kenny, A. D. (eds.). Parkinson’s Disease, pp. 131–149. ( New York and London: Plenum Press )

    Google Scholar 

  • Stern, G. M. and Lees, A. J. (1978). Choice of treatments in Parkinson’s disease. Practitioner, 219, 537

    Google Scholar 

  • Pearce, I, and Pearce, J. M. S. (1978). Bromocriptine in Parkinsonism. Br. Med. J, 1, 1402

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Marion Hildick-Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Northwick Park Hospital and Clinical Research Centre, Watford Road, HA1 3JUJ, Harrow, Middlesex, UK

    M. J. Denham

Rights and permissions

Reprints and permissions

Copyright information

© 1980 MTP Press Limited

About this chapter

Cite this chapter

Hildick-Smith, M. (1980). Management of Parkinson’s disease in the elderly. In: Denham, M.J. (eds) The Treatment of Medical Problems in the Elderly. Current Status of Modern Therapy, vol 3. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-6223-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-6223-4_6

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-011-6225-8

  • Online ISBN: 978-94-011-6223-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation